Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention TG Therapeutics, Inc., the most common co-covered peer. Briumvi appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention TG Therapeutics, Inc., the most common co-covered peer. Briumvi appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Briumvi. Shared-story counts are live from our verified record — not editorial picks.
Quantitative investment firm Winton Group Ltd has acquired 113,951 shares of TG Therapeutics, signaling strong institutional confidence in the biotech firm's commercial trajectory. The move comes as TG Therapeutics continues to gain market share in the Multiple Sclerosis sector with its flagship therapy, Briumvi.
Source: dailypolitical.com · tickerreport.com
Briumvi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
